PE20020287A1 - Procedimiento para la purificacion de un antigeno del virus de la hepatitis b - Google Patents

Procedimiento para la purificacion de un antigeno del virus de la hepatitis b

Info

Publication number
PE20020287A1
PE20020287A1 PE2001000786A PE2001000786A PE20020287A1 PE 20020287 A1 PE20020287 A1 PE 20020287A1 PE 2001000786 A PE2001000786 A PE 2001000786A PE 2001000786 A PE2001000786 A PE 2001000786A PE 20020287 A1 PE20020287 A1 PE 20020287A1
Authority
PE
Peru
Prior art keywords
antigen
hepatitis
procedure
refers
virus
Prior art date
Application number
PE2001000786A
Other languages
English (en)
Inventor
Heyder Koen De
Peter Schu
Michelle Serantoni
Opstal Omer Van
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0019728.5A external-priority patent/GB0019728D0/en
Priority claimed from GB0101334A external-priority patent/GB0101334D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of PE20020287A1 publication Critical patent/PE20020287A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE REFIERE A UN PROCEDIMIENTO PARA LA PRODUCCION DE UN ANTIGENO DEL VIRUS DE LA HEPATITIS B PARA USO EN UNA VACUNA QUE COMPRENDE LA PURIFICACION DEL ANTIGENO EN PRESENCIA DE UN AGENTE REDUCTOR QUE TIENE EL GRUPO SH LIBRE TAL COMO CISTEINA, GLUTATION, DITIOTREITOL, ß-MERCAPTEROL Y LA PREPARACION BRUTA DE ANTIGENO SE SOMETE A: i) CROMATOGRAFIA DE EXCLUSION MOLECULAR; ii) CROMATOGRAFIA DE INTERCAMBIO IONICO Y iii) MEZCLA CON UN AGENTE REDUCTOR. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA PRODUCIR UN ANTIGENO SIN TRAZAS DE TIOMERSAL DONDE EL ANTIGENO INMUNOGENICO ESTABLE COMPRENDE POR LO MENOS 0,025ug DE MERCURIO POR 20ug DE PROTEINA. LA CISTEINA SE ANADE A UNA CONCENTRACION FINAL COMPRENDIDA ENTRE 1 Y 10 mM. EL ANTIGENO INMUNOGENICO DE LA HEPATITIS B TIENE UNA RELACION MEDIA DE PROTEINA ELISA MAYOR DE 1,5 Y UNA CI50 AL MENOS 3 VECES MENOR QUE EL ANTIGENO SUPERFICIAL DE LA HEPATITIS B FABRICADO EN PRESENCIA DE TIOMERSAL. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) UN ANTIGENO; b) UN ADYUVANTE COMO LA SAL DE ALUMINIO, UN ADYUVANTE DE INDUCCION TH1, EL COMPUESTO 3-DPML, OLIGONUCLEOTIDO CpG; C) COMPRENDE ADEMAS UNO O MAS ANTIGENOS SELECCIONADOS DE TOXOIDE DIFTERICO, TOXOIDE TETANICO, VIRUS DE LA POLIO, ENTRE OTROS
PE2001000786A 2000-08-10 2001-08-08 Procedimiento para la purificacion de un antigeno del virus de la hepatitis b PE20020287A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0019728.5A GB0019728D0 (en) 2000-08-10 2000-08-10 Novel treatment
GB0101334A GB0101334D0 (en) 2001-01-18 2001-01-18 Novel compounds

Publications (1)

Publication Number Publication Date
PE20020287A1 true PE20020287A1 (es) 2002-06-20

Family

ID=26244821

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000786A PE20020287A1 (es) 2000-08-10 2001-08-08 Procedimiento para la purificacion de un antigeno del virus de la hepatitis b

Country Status (36)

Country Link
US (3) US20030235590A1 (es)
EP (2) EP1307473B1 (es)
JP (2) JP2004505992A (es)
KR (1) KR100804922B1 (es)
CN (1) CN1468256B (es)
AP (1) AP2003002734A0 (es)
AR (1) AR030325A1 (es)
AT (2) ATE313558T1 (es)
AU (2) AU8207301A (es)
BG (1) BG66038B1 (es)
BR (1) BRPI0113155C1 (es)
CA (2) CA2740282A1 (es)
CY (2) CY1106310T1 (es)
CZ (1) CZ303217B6 (es)
DE (2) DE60136400D1 (es)
DK (2) DK1307473T3 (es)
DZ (1) DZ3470A1 (es)
EA (1) EA006433B1 (es)
EG (1) EG25829A (es)
ES (2) ES2314555T3 (es)
HK (1) HK1056884A1 (es)
HU (1) HU228932B1 (es)
IL (2) IL154301A0 (es)
MX (1) MXPA03001235A (es)
MY (1) MY128999A (es)
NO (1) NO20030635L (es)
NZ (1) NZ524012A (es)
OA (1) OA12361A (es)
PE (1) PE20020287A1 (es)
PL (1) PL204736B1 (es)
PT (1) PT1666487E (es)
SI (2) SI1666487T1 (es)
SK (2) SK288079B6 (es)
UA (1) UA79735C2 (es)
UY (1) UY26882A1 (es)
WO (1) WO2002012287A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
GB0202901D0 (en) * 2002-02-07 2002-03-27 Glaxosmithkline Biolog Sa Novel vaccine
KR20080043775A (ko) * 2005-07-11 2008-05-19 글로브이뮨 표적 치료용 회피 돌연변이체에 대한 면역 반응의 유발방법 및 조성물
AP2745A (en) * 2005-08-02 2013-09-30 Novartis Vaccines & Diagnostic Reducing interference between oil-containing adjuvants and surfactant-containing antigens
GB0522765D0 (en) * 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
GB0612142D0 (en) 2006-06-20 2006-08-02 Secr Defence Spreading modulation spectrum control
PT2097102E (pt) 2006-09-07 2012-08-03 Glaxosmithkline Biolog Sa Vacina de combinação tendo quantidades reduzidas de antigénio de poliovírus
US20100074918A1 (en) 2007-05-02 2010-03-25 Jan Poolman Vaccine
JP5214627B2 (ja) * 2007-10-30 2013-06-19 京セラ株式会社 弾性波装置
US8250102B2 (en) * 2008-03-14 2012-08-21 Microsoft Corporation Remote storage and management of binary object data
KR100959145B1 (ko) 2008-03-21 2010-05-25 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사 입자의 생산 및 정제 방법
US9415006B2 (en) * 2008-05-23 2016-08-16 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
AU2010252012A1 (en) * 2009-05-27 2011-12-22 Glaxosmithkline Biologicals S.A. CASB7439 constructs
DK2705365T3 (en) * 2011-01-14 2016-10-24 Hal Allergy Holding B V Immunoassay for the direct determination of the antigen content in the products containing the adjuvant-linked antigen particles
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
CN106222129A (zh) * 2016-07-29 2016-12-14 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
EP3655024A1 (en) 2017-07-18 2020-05-27 Serum Institute of India Private Limited An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
WO2020178359A1 (en) 2019-03-05 2020-09-10 Glaxosmithkline Biologicals Sa Hepatitis b immunisation regimen and compositions
CA3161638A1 (en) * 2019-12-13 2021-06-17 Jun Ge Pharmaceutical composition and use thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1030777A (en) * 1963-12-06 1966-05-25 Ciba Ltd Method of preparing a vaccine against trypanosoma cruzi infections
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4720385A (en) * 1983-03-29 1988-01-19 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
JPS6013718A (ja) 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst Ｂ型肝炎ワクチン
EP0135435A3 (en) 1983-08-22 1987-03-25 Merck & Co. Inc. Immunogenic hbsag derived from transformed yeast
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4649192A (en) * 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
AP56A (en) 1987-01-30 1989-09-26 Smithkline Biologicals S A Hepatitis B virus surface antigens and hybrid antigehs containing them.
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
EP0304578B1 (en) 1987-06-22 2001-10-24 Medeva Holdings Bv Peptide comprising hepatitis B surface antigen
EP0299108B1 (en) 1987-07-17 1994-05-18 Rhein Biotech Gesellschaft für biotechnologische Prozesse und Produkte mbH DNA-molecules coding for FMDH control regions and structured gene for a protein having FMDH-activity and their uses
EP0314240A3 (en) 1987-10-26 1990-03-28 Merck & Co. Inc. Process for purifying recombinant hepatitis antigens
JPH085804B2 (ja) 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5242812A (en) * 1989-02-07 1993-09-07 Bio-Technology General Corp. Method for production and purification of hepatitis B vaccine
US5274081A (en) * 1989-09-20 1993-12-28 Immuno A.G. Complex suitable for carrying out a method of purifying pre-S hepatitis B surface antigen
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
AU9052091A (en) 1990-12-20 1992-07-22 Smithkline Beecham Biologicals (Sa) Vaccines based on hepatitis b surface antigen
JP3026029B2 (ja) 1991-04-26 2000-03-27 財団法人阪大微生物病研究会 組換え水痘ウイルスとその作製法
JPH06503231A (ja) 1991-09-18 1994-04-14 アムジエン・インコーポレーテツド 胆汁酸塩を含有するｂ型肝炎ワクチン製剤
US6620414B2 (en) * 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
JP3755890B2 (ja) 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
HUT78048A (hu) * 1994-10-24 1999-07-28 Ophidian Pharmaceuticals, Inc. A C. difficile által okozott betegség kezelésére és megelőzésére szolgáló vakcina és antitoxin
KR960023066A (ko) * 1994-12-10 1996-07-18 성재갑 전에스 (s) 2 펩티드 함유 비 (b) 형 간염 표면항원의 정제 방법
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
HUP0101047A3 (en) * 1998-03-09 2004-10-28 Smithkline Beecham Biolog Combined vaccine compositions
DE69929444T2 (de) 1998-08-10 2006-09-28 Antigenics Inc., Woburn Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
AU2212100A (en) * 1998-12-23 2000-07-12 Merck & Co., Inc. Improved recombinant hepatitis b surface antigen
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах

Also Published As

Publication number Publication date
SK288079B6 (sk) 2013-06-03
SI1307473T1 (sl) 2006-04-30
CY1106310T1 (el) 2011-10-12
UA79735C2 (uk) 2007-07-25
CZ2003385A3 (cs) 2003-06-18
DK1666487T3 (da) 2009-01-12
ATE412665T1 (de) 2008-11-15
HK1056884A1 (en) 2004-03-05
DE60116107T2 (de) 2006-08-03
ES2314555T3 (es) 2009-03-16
KR100804922B1 (ko) 2008-02-20
JP2004505992A (ja) 2004-02-26
NZ524012A (en) 2004-02-27
CN1468256A (zh) 2004-01-14
EA200300129A1 (ru) 2003-10-30
BG107545A (bg) 2004-01-30
EP1666487B1 (en) 2008-10-29
HU228932B1 (en) 2013-06-28
ATE313558T1 (de) 2006-01-15
IL154301A0 (en) 2003-09-17
KR20030029127A (ko) 2003-04-11
AU2001282073B2 (en) 2005-01-20
BG66038B1 (bg) 2010-11-30
PL362322A1 (en) 2004-10-18
MY128999A (en) 2007-03-30
MXPA03001235A (es) 2004-07-16
UY26882A1 (es) 2002-03-22
US20030235590A1 (en) 2003-12-25
BRPI0113155C1 (pt) 2021-05-25
EG25829A (en) 2012-09-02
EA006433B1 (ru) 2005-12-29
BRPI0113155B1 (pt) 2018-11-21
EP1307473A1 (en) 2003-05-07
JP2012255015A (ja) 2012-12-27
US8624004B2 (en) 2014-01-07
NO20030635L (no) 2003-04-01
HUP0302951A2 (hu) 2003-12-29
SI1666487T1 (sl) 2009-02-28
CA2740282A1 (en) 2002-02-11
HUP0302951A3 (en) 2004-10-28
PT1666487E (pt) 2008-12-26
PL204736B1 (pl) 2010-02-26
EP1666487A1 (en) 2006-06-07
AU8207301A (en) 2002-02-18
AR030325A1 (es) 2003-08-20
CY1108789T1 (el) 2014-04-09
OA12361A (en) 2004-04-13
US20060159705A1 (en) 2006-07-20
DZ3470A1 (fr) 2002-02-14
NO20030635D0 (no) 2003-02-07
BR0113155A (pt) 2003-07-08
ES2254464T3 (es) 2006-06-16
IL154301A (en) 2009-11-18
EP1307473B1 (en) 2005-12-21
DK1307473T3 (da) 2006-05-01
CN1468256B (zh) 2010-10-27
BRPI0113155B8 (pt) 2019-08-13
CZ303217B6 (cs) 2012-05-30
DE60136400D1 (de) 2008-12-11
SK288069B6 (sk) 2013-05-03
US20090123496A1 (en) 2009-05-14
CA2427475C (en) 2011-07-05
SK1692003A3 (en) 2003-08-05
DE60116107D1 (de) 2006-01-26
JP5559847B2 (ja) 2014-07-23
CA2427475A1 (en) 2002-02-11
WO2002012287A1 (en) 2002-02-14
AP2003002734A0 (en) 2003-03-31

Similar Documents

Publication Publication Date Title
PE20020287A1 (es) Procedimiento para la purificacion de un antigeno del virus de la hepatitis b
DK1090033T4 (da) Partikler af HCV-kappeproteiner: Anvendelse til vaccination
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
ATE320493T1 (de) Modifizierung des hepatitis b kernantigens
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
DE60045668D1 (de) Influenzavirus-Impfstoffzusammensetzung
DE60109443D1 (de) Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält
HUP0301180A2 (hu) Imidazokinolinaminok adjuvánsként való használata DNS vakcinálásban
GB0105877D0 (en) Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immunize against flavivirus and otherinfecti
CO6300963A2 (es) Una vacuna contra la malaria que comprende p. falciparum y p. vivax
BR0207988A (pt) Cepas atenuadas vivas de vìrus de prrs
CY1112149T1 (el) Μειωση της παρεμβολης μεταξυ επικουρων που περιεχουν ελαιο και αντιγονων που περιεχουν τασιενεργο
HUP0202770A2 (hu) Humán papillómavírus oltóanyag
AR027291A1 (es) Atenuacion recombinante de prrsv
ATE303821T1 (de) Neue vakzinformulierung aus dna-vakzine- inaktiviertem virus
ES2139083T3 (es) Composiciones de vacuna.
AR124384A1 (es) Parapoxvirus modificado que tiene inmunogenicidad aumentada
RU2004104357A (ru) Вакцинный состав, потенцированный комбинацией днк и антигена
ATE431745T1 (de) Ltb4 als adjuvans für impfstoffe
DE602004028512D1 (de) Rekombinante vakzine gegen infektion mit dem japanischen enzephalitis-virus äjevü und verfahren davon
ECSP034474A (es) Nuevo tratamiento
UY27030A1 (es) Inhibidores del virus de hepatitis c

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed